Moody National Bank Trust Division bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 888 shares of the company’s stock, valued at approximately $311,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Renaissance Technologies LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth about $4,807,000. Schroder Investment Management Group lifted its position in shares of IDEXX Laboratories by 9.2% during the fourth quarter. Schroder Investment Management Group now owns 160,377 shares of the company’s stock worth $105,602,000 after purchasing an additional 13,473 shares in the last quarter. Siemens Fonds Invest GmbH lifted its position in shares of IDEXX Laboratories by 26.9% during the fourth quarter. Siemens Fonds Invest GmbH now owns 4,319 shares of the company’s stock worth $2,856,000 after purchasing an additional 916 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of IDEXX Laboratories by 0.4% during the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 96,951 shares of the company’s stock worth $63,838,000 after purchasing an additional 422 shares in the last quarter. Finally, Alerus Financial NA lifted its position in shares of IDEXX Laboratories by 390.2% during the fourth quarter. Alerus Financial NA now owns 2,294 shares of the company’s stock worth $1,510,000 after purchasing an additional 1,826 shares in the last quarter. 88.45% of the stock is owned by institutional investors.
IDEXX Laboratories Trading Down 0.8 %
IDXX opened at $339.67 on Tuesday. The firm’s fifty day moving average is $373.36 and its two-hundred day moving average is $412.13. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.61 and a current ratio of 0.89. The firm has a market cap of $28.28 billion, a PE ratio of 43.83, a price-to-earnings-growth ratio of 4.57 and a beta of 1.16. IDEXX Laboratories, Inc. has a twelve month low of $318.50 and a twelve month high of $689.95.
Wall Street Analyst Weigh In
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.